Talía Velasco-Hernández

The paper develops patient-derived AML PDX models that replicate primary AML biology and include subgroups lacking existing models, showing reduced leukemia growth after long-term chemotherapy.

This paper develops and validates a dual-targeting CAR-T cell therapy for T-ALL that targets CCR9 and CD1a, showing improved efficacy and safety compared to single-targeting approaches.